Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 18  |  Issue : 78  |  Page : 256-260

Commigileadin A: A new triterpenoid from Commiphora gileadensis aerial parts


1 Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
2 Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
3 Department of Chemistry, Preparatory Year Program, Batterjee Medical College, Jeddah, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt

Correspondence Address:
Gamal A Mohamed
Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah - 21589
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_118_21

Rights and Permissions

Background: Genus Commiphora (Burseraceae) includes about 150 species of aromatic shrubs located in Africa, India, and the Arabian region. C. gileadensis L. has been used for treating several ailments such as constipation, urinary retention, headache, jaundice, joint pain, liver and stomach diseases, and inflammatory disorders. Objectives: In this work, a phytochemical investigation of C. gileadensis aerial parts was carried out. Moreover, the antimicrobial potential of the new metabolite was assessed. Materials and Methods: The aerial parts were extracted at room temperature with methanol (MeOH). The MeOH extract was subjected to various chromatographic techniques to separate the bio-constituents. Their structures were exhaustively specified by utilizing diversified spectroscopic data and comparing them with the literature. The antimicrobial potential of the new compound 1 was assessed toward Bacillus cereus, Escherichia coli, Staphylococcus aureus, and Clostridium albicans. Results: A new friedelan triterpenoid, commigileadin A [3,11-dioxo-(D: A)-friedo-olean-27-al] (1) and four known metabolites, namely, Stigmasterol (2), naringenin (3), naringenin-4-methyl ether (4), and kaempferol (5) were obtained. Compound 1 possessed moderate activity toward B. cereus (inhibition zone diameter (IZD): 12.6 mm and minimum inhibitory concentration [MIC]: 8.9 μg/mL) in comparison to ciprofloxacin (IZD: 21.1 mm and MIC: 2.5 μg/mL, respectively). Conclusion: This work reported the characterization of a new triterpenoid (1) and four known constituents (2-5). Compound 1 possessed a moderate activity toward B. cereus.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed883    
    Printed32    
    Emailed0    
    PDF Downloaded201    
    Comments [Add]    

Recommend this journal